Caffeine may interfere with oral minoxidil because caffeine increases blood pressure while minoxidil lowers it. Users discuss potential interactions and effects on hair loss treatment.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
A user plans to create a copper peptide hair serum with GHK-Cu and AHK-Cu, considering adding 5% minoxidil but avoiding finasteride and dutasteride. They seek suggestions for improving the product without complicating it.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.
A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.
The conversation discusses using RU58841 at a 2% concentration as an alternative due to side effects from finasteride. The user plans to start with a lower concentration and increase if necessary.
Creatine monohydrate's potential link to hair loss, with mixed opinions on its effects. Treatments like minoxidil, finasteride, and RU58841 are discussed.
The conversation humorously discusses hair loss treatments, including Minoxidil, finasteride, RU58841, and topical 17 alpha estradiol, with some users joking about transitioning to female to avoid baldness. The overall tone is satirical, emphasizing self-acceptance and the lengths people might consider for hair restoration.